Pulmatrix Appoints Mark Iwicki Chairman of the Board
LEXINGTON, Mass., Dec. 8, 2015 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a biopharmaceutical company developing inhaled therapies for pulmonary disease, today announced the appointment of Mark Iwicki as chairman of its board of directors. Terry McGuire, who has served as chairman since June 18, 2015, will retain his seat on the board and another director, David Maki, will vacate his seat while remaining an advisor to the company on intellectual property matters.
Robert Clarke, PhD, Pulmatrix's president and CEO, said, "Mark's outstanding track record building biopharmaceutical businesses will serve us well as we continue to develop Pulmatrix's pipeline of drugs for cystic fibrosis, chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis."
Mr. Iwicki has 25 years of experience as a pharmaceutical industry leader managing all stages of drug development and commercialization in multiple therapeutic areas including respiratory. He was CEO of Civitas Pharmaceuticals, a biotechnology company with a novel pulmonary drug delivery platform, and also led the development and launch of several respiratory products as CEO of Sunovion Pharmaceuticals and during his tenure at Novartis. Mr. Iwicki is currently on the boards of directors of Kala Pharmaceuticals, Aimmune, Nimbus Therapeutics, Merus and Taris Biomedical.
"Pulmatrix has demonstrated great innovation in developing inhaled therapies to address pulmonary conditions, and I look forward to working with its board and management to advance this mission," Mr. Iwicki said.
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis (CF), as well as PUR1500, an inhaled product for the treatment of idiopathic pulmonary fibrosis. In addition, Pulmatrix is pursuing opportunities in major pulmonary diseases through collaborations, including PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease (COPD).
SOURCE Pulmatrix, Inc.